Holen Sie sich die Stockscreener-App
26.93
5.77%
-1.65
Handel nachbörslich:
27.06
0.13
+0.48%
Schlusskurs vom Vortag:
$28.58
Offen:
$28.99
24-Stunden-Volumen:
948.81K
Relative Volume:
0.69
Marktkapitalisierung:
$968.73M
Einnahmen:
$117.67M
Nettoeinkommen (Verlust:
$-1.88B
KGV:
-0.4449
EPS:
-60.5369
Netto-Cashflow:
$-621.36M
1W Leistung:
-11.09%
1M Leistung:
-31.45%
6M Leistung:
+87.01%
1J Leistung:
+0.00%
1-Tages-Spanne:
$26.16
$28.99
1-Wochen-Bereich:
$26.16
$33.49
52-Wochen-Spanne:
$12.33
$63.99
Grail Inc Stock (GRAL) Company Profile
Firmenname
Grail Inc
Sektor
Branche
Telefon
(833) 694-2553
Adresse
1525 O'BRIEN DRIVE, MENLO PARK
Vergleichen Sie GRAL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GRAL
Grail Inc
|
26.93 | 968.73M | 117.67M | -1.88B | -621.36M | -60.54 |
|
TMO
Thermo Fisher Scientific Inc
|
500.16 | 196.14B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
205.85 | 150.17B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
415.87 | 34.36B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
116.69 | 33.28B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
177.39 | 31.62B | 15.41B | 1.37B | 2.11B | 7.50 |
Grail Inc Stock (GRAL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-27 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-10-17 | Eingeleitet | Guggenheim | Neutral |
Grail Inc Aktie (GRAL) Neueste Nachrichten
A Sydney company’s laser focus on energy’s holy grail - @AuManufacturing
Opinion | One ‘Monopoly’ That Could Save Your Life - The Wall Street Journal
FDA approval remains Holy Grail for Aussie biotechs - NT News
Biocurious: FDA approval remains the Holy Grail for ASX life science stocks - Stockhead
Grail price target raised to $20 from $16 at Morgan Stanley - TipRanks
Have Insiders Sold GRAIL Shares Recently? - Simply Wall St
Jim Cramer On Netflix, Inc. (NFLX) – Subscription Is the Holy Grail—Netflix Is Doing Very Well! - Insider Monkey
Illumina Wins Court Fight With EU Over $7 Billion Grail Deal - MSN
Grail president Joshua Ofman sells $65,800 in common stock By Investing.com - Investing.com Australia
Grail CEO Robert Ragusa sells $237,976 in stock By Investing.com - Investing.com Canada
Grail CEO Robert Ragusa sells $237,976 in stock - Investing.com India
Grail president Joshua Ofman sells $65,800 in common stock - Investing.com
Oppenheimer & Co. Inc. Invests $190,000 in Grail, Inc. (NASDAQ:GRAL) - Defense World
Rhumbline Advisers Makes New Investment in Grail, Inc. (NASDAQ:GRAL) - Defense World
New York State Common Retirement Fund Makes New $59,000 Investment in Grail, Inc. (NASDAQ:GRAL) - Defense World
GRALGrail Inc Latest Stock News & Market Updates - StockTitan
Is GRAIL, Inc. (GRAL) Among Jeff Bezos’ Investments in 2025? - Yahoo Finance
Jeff Bezos Investments in 2025: 12 Companies Bezos Is Investing In - Insider Monkey
Ieq Capital LLC Acquires Shares of 19,874 Grail, Inc. (NASDAQ:GRAL) - MarketBeat
Grail (NASDAQ:GRAL) Trading 9.8% HigherWhat's Next? - MarketBeat
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PR Newswire
Grail goes ‘Grey’s’: Actor Kate Walsh joins awareness campaign for multi-cancer early detection testing - FiercePharma
GRAIL Partners With Actress Kate Walsh for Generation Possible to Raise Awareness of Multi-Cancer Early Detection Testing - Longview News-Journal
Grail projects FDA submission completion for Galleri by H1 2026 with expanded scalability - MSN
GRAIL, Inc. (GRAL): Among the Best Performing Small Cap Stocks So Far In 2025 - Insider Monkey
Why Grail (GRAL) Is Falling Today - MSN
Van ECK Associates Corp Takes $475,000 Position in Grail, Inc. (NASDAQ:GRAL) - Defense World
Grail initiated at equal weight by Morgan Stanley - MSN
Can GRAIL's Cancer Detection Technology Transform Healthcare? Key Presentation Coming March 4 - StockTitan
Putting early cancer detection to the test - Nature.com
GRAIL Q4 Loss Narrows, Revenue Up; Shares Rise After-Hours -February 20, 2025 at 05:36 pm EST - Marketscreener.com
Earnings call transcript: Grail’s Q4 2024 revenue rises, stock surges - Investing.com
Earnings call transcript: Grail’s Q4 2024 revenue rises, stock surges By Investing.com - Investing.com Nigeria
Grail reports Q4 EPS ($2.89) vs. ($6.04) last year - TipRanks
Earnings call transcript: Grail's Q4 2024 revenue rises, stock surges By Investing.com - Investing.com UK
GRAIL Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Earnings Flash (GRAL) GRAIL INC. Posts Q4 Revenue $38.3M, vs. FactSet Est of $34.4M - Marketscreener.com
Can GRAIL's 137,000 Cancer Test Sales Overcome Its $2B Loss? Key Earnings Insights - StockTitan
Grail Inc options imply 13.5% move in share price post-earnings - TipRanks
Golden Grail Beverages Announces Termination of UPDC Beverages Asset Purchase Agreement - GlobeNewswire
Investors Eye Biotech Sector as Cancer Therapy Market Surges - The Globe and Mail
We're Keeping An Eye On GRAIL's (NASDAQ:GRAL) Cash Burn Rate - Yahoo Finance
Grail Inc expected to post a loss of $7.05 a shareEarnings Preview - TradingView
Grail, Inc. (NASDAQ:GRAL) Short Interest Update - Defense World
Grail rallies 30% in wake of Quest agreement - MSN
Grail (NASDAQ:GRAL) Trading 5.4% HigherWhat's Next? - MarketBeat
Finanzdaten der Grail Inc-Aktie (GRAL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.80%
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):